广济药业(000952) - 2025 Q2 - 季度业绩预告

Hubei Guangji Pharmaceutical Co., Ltd. 2025 Interim Results Forecast The company forecasts a continued net loss for H1 2025, but with a significant year-over-year reduction Performance Forecast for the Current Period The company anticipates a net loss attributable to shareholders for H1 2025, but with a notable reduction compared to the prior year H1 2025 Performance Forecast | Item | Current Reporting Period | Same Period Last Year | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss: RMB 67.00 million - 83.50 million | Loss: RMB 106.65 million | | YoY Change | Loss Reduction: 21.70% - 37.17% | - | | Net Profit after Non-recurring Items | Loss: RMB 70.00 million - 86.50 million | Loss: RMB 115.67 million | | YoY Change | Loss Reduction: 25.22% - 39.48% | - | | Basic Earnings Per Share | Loss: RMB 0.1915/share - 0.2387/share | Loss: RMB 0.3014/share | Communication with the Accounting Firm The company has communicated with its accounting firm regarding the forecast, with no disagreements on the content - The company has pre-communicated with its accounting firm regarding the performance forecast, and no disagreements exist between the two parties[4] - This performance forecast has not been audited by a certified public accountant[4] Explanation of Performance Changes The year-over-year improvement in net profit is attributed to cost reduction, subsidiary adjustments, and sales growth Management Optimization and Cost Control The company enhanced management efficiency and lowered costs by streamlining its organizational structure - During the reporting period, the company restructured its management organization based on the principle of 'streamlined and efficient' to improve management effectiveness and reduce administrative costs[5] Subsidiary Operational Adjustments The Jining subsidiary reduced its losses year-over-year by scaling back production and personnel due to unfavorable market prices - The Jining subsidiary reduced its losses year-over-year by systematically scaling back production and non-essential personnel in response to lower-than-expected market prices[5] Market and Sales Expansion The company achieved sales growth for certain products by strengthening market cooperation and expanding sales channels - The company achieved year-over-year sales growth for certain specifications of its raw material and formulation series products by strengthening market partnerships and expanding sales channels[5] Risk Warning The performance forecast is a preliminary estimate, and final data will be in the official interim report - This performance forecast is a preliminary result from the company's finance department; specific financial data will be based on the official 2025 interim report[6] - Investors are advised to make prudent decisions and be aware of investment risks[6]